Clinical trial experience with extended-release niacin (niaspan): dose-escalation study

This publication has 16 references indexed in Scilit:

• The prevalence of side effects with regular and sustained-release nicotinic acid
  The American Journal of Medicine, 1995
• Efficacy and Safety of Controlled-Release Niacin in Dyslipoproteinemic Veterans
  Annals of Internal Medicine, 1994
• The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover
  Atherosclerosis, 1993
• Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B
  New England Journal of Medicine, 1990
• Niacin and Hepatic Failure
  Annals of Internal Medicine, 1989
• Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid
  Journal of Internal Medicine, 1989
• Fulminant Hepatic Failure after Ingestion of Sustained-Release Nicotinic Acid
  Annals of Internal Medicine, 1989
• Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin
  JACC, 1986
• Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin
  Metabolism, 1985
• Clofibrate and Niacin in Coronary Heart Disease
  JAMA, 1975